About VaxForm
VaxForm is a Healthcare company based in Lehigh (United States) founded in 2010. Vaccine formulation development and consulting services are offered. VaxForm offers products and services including QYNDR Platform and Oral COVID Vaccine. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Vaccines. Its legal entity is VaxForm LLC. Its competitors include Fina Biosolutions and Primrose Bio; 2 of its 2 listed competitors have raised funding.
Company details
VaxForm is exclusively focused on the development of vaccine products and their formulations. It also provides consulting services in the area of vaccine formulation development and assists its clients through the different phases of vaccine formulation development right from preclinical stage to commercialization. They offer their services right from project definition to implementation for mono- or multivalent bacterial or viral antigen formulations, vaccine combinations, and live attenuated vaccines. The company claims to have expertise in the formulation of vaccine targets including Pneumococcal recombinant proteins, Combination vaccines, and Staph enterotoxins. VaxForm has signed RD agreements from United States Army Medical Research Institute for infectious diseases and Tamarisk Technologies (an early stage drug delivery technology company). VaxForm has also received Small Business Technology Transfer Program (STTR) grants from the US DoD to develop a recombinant fusion protein vaccine targeting diseases resulting from Streptococcus pyogenes infection.
- Headquarters Lehigh, United States
- SectorsHealthcare
- Email••••••••
- Website vaxform.com
- Social LinkedIn
- Legal Name Vaxform Llc
- Latest Funding Round$256K (USD), Grant
Sep 2020
- InvestorsNIH
& 1 more
Products & Services of VaxForm
VaxForm offers a comprehensive portfolio of products and services, including QYNDR Platform and Oral COVID Vaccine.
Technology for creating oral COVID vaccines through research and innovation.
Vaccine designed to prevent COVID-19 via oral administration.
Funding Insights of VaxForm
- Total Rounds 5
- Last Round Grant — $256,000
- Investors Count 2
All 5 funding rounds of VaxForm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $256,000 | Grant | – | – | |
| Feb 2019 | $225,000 | Grant | – | – | |
| Sep 2013 | $750,000 | Grant | – | – | |
| Jul 2012 | Grant | – | – | ||
| Nov 2010 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in VaxForm
VaxForm has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for VaxForm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VaxForm
2 people are tracked at VaxForm (2 in leadership).
| Name | Role | Group |
|---|---|---|
Garry Morefield | President | Leadership |
Elaine Morefield | Vice President | Leadership |
Complete people profiles for VaxForm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VaxForm
3 dated milestones of VaxForm across 10 years, from founding to its latest funding, stage changes and deals.
- Founded VaxForm is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $256K.
Competitors of VaxForm
VaxForm has 2 listed competitors in our database, 2 of them funded. They include Fina Biosolutions and Primrose Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| finabio.net | 2006 | Rockville, United States | $3M | Biotechnology company specializing in bioconjugation services mainly for vaccine development | ||
| primrosebio.com | 2023 | San Diego, United States | $15M | New molecules are discovered, developed, and manufactured in biotechnology. |
Detailed competitors of VaxForm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as VaxForm (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vaxform
Complete news archive for VaxForm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VaxForm
VaxForm was founded in 2010.
VaxForm is headquartered in Lehigh, United States.
VaxForm is exclusively focused on the development of vaccine products and their formulations. It also provides consulting services in the area of vaccine formulation development and assists its clients through the different phases of vaccine formulation development right from preclinical stage to commercialization. They offer their services right from project definition to implementation for mono- or multivalent bacterial or viral antigen formulations, vaccine combinations, and live attenuated vaccines. The company claims to have expertise in the formulation of vaccine targets including Pneumococcal recombinant proteins, Combination vaccines, and Staph enterotoxins. VaxForm has signed RD agreements from United States Army Medical Research Institute for infectious diseases and Tamarisk Technologies (an early stage drug delivery technology company). VaxForm has also received Small Business Technology Transfer Program (STTR) grants from the US DoD to develop a recombinant fusion protein vaccine targeting diseases resulting from Streptococcus pyogenes infection.
VaxForm's top competitors include Fina Biosolutions and Primrose Bio.
VaxForm offers QYNDR Platform and Oral COVID Vaccine.
VaxForm has 2 investors. Key investors include NIH, and National Science Foundation.
VaxForm operates through Vaxform Llc.